Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema. Pilot study of the Pan-American Collaborative Retina Study Group

Journal of Cataract and Refractive Surgery

Volumn 33, Issue 12, 2007, Pages 2098-2105

  Arevalo, J Fernando ^a   Garcia Amaris, Rafael A ^a   Roca, Jose A ^a   Sanchez, Juan G ^a   Wu, Lihteh ^a   Berrocal, Maria H ^a   Maia, Mauricio ^a  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT EXTRACTION; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PSEUDOPHAKIA; RETREATMENT; RETROSPECTIVE STUDIES; SOUTH AMERICA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 36448946551     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2007.07.046     Document Type: Article

References (36)

1. Irvine S.R. A newly defined vitreous syndrome following cataract surgery; interpreted according to recent concepts of the structure of the vitreous; the Seventh Francis I. Proctor Lecture. Am J Ophthalmol 36 (1953) 599-619
2. Flach A.J. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 96 (1998) 557-634. Available at: http://www.pubmedcentral.nih.gov/tocrender.fcgi?iid=124633 Accessed August 29, 2007
3. Spaide R.F., Yannuzzi L.A., and Sisco L.J. Chronic cystoid macular edema and predictors of visual acuity. Ophthalmic Surg 24 (1993) 262-267
4. Levin D.S., and Lim J.I. Update on pseudophakic cystoid macular edema treatment options. Ophthalmol Clin North Am 15 4 (2002) 467-472
5. Stark Jr. W.J., Maumenee A.E., Fagadau W., et al. Cystoid macular edema in pseudophakia. Surv Ophthalmol 28 (1984) 442-451
6. Mentes J., Erakgün T., Afrashi F., and Kerci G. Incidence of cystoid macular edema after uncomplicated phacoemulsification. Ophthalmologica 217 (2003) 408-412
7. Ursell P.G., Spalton D.J., Whitcup S.M., and Nussenblatt R.B. Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg 25 (1999) 1492-1497
8. Tranos P.G., Wickremasinghe S.S., Stangos N.T., et al. Macular edema. Surv Ophthalmol 49 (2004) 470-490
9. Abe T., Hayasaka S., Nagaki Y., et al. Pseudophakic cystoid macular edema treated with high-dose intravenous methylprednisolone. J Cataract Refract Surg 25 (1999) 1286-1288
10. Thach A.B., Dugel P.U., Flindall R.J., et al. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology 104 (1997) 2003-2008
11. Karacorlu M., Ozdemir H., and Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 81 (2003) 648-652
12. Conway M.D., Canakis C., Livir-Rallatos C., and Peyman G.A. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 29 (2003) 27-33
13. Riley A.F., Wakely L.A., Patel H.Y., et al. Use of a cyclo-oxygenase 2 inhibitor for prophylaxis of cystoid macular oedema following cataract surgery: a randomized placebo-controlled trial. Clin Exp Ophthalmol 34 (2006) 299-304
14. Sivaprasad S., Bunce C., and Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 89 (2005) 1420-1422
15. Rho D.S. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 29 (2003) 2378-2384
16. Tripathi R.C., Fekrat S., Tripathi B.J., and Ernest J.T. A direct correlation of the resolution of pseudophakic cystoid macular edema with acetazolamide therapy. Ann Ophthalmol 23 (1991) 127-129
17. Grover S., Apushkin M.A., and Fishman G.A. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 141 (2006) 850-858
18. Steinert R.F., and Wasson P.J. Neodymium:YAG laser anterior vitreolysis for Irvine-Gass cystoid macular edema. J Cataract Refract Surg 15 (1989) 304-307
19. Pfoff D.S., and Thom S.R. Preliminary report on the effect of hyperbaric oxygen on cystoid macular edema. J Cataract Refract Surg 13 (1987) 136-140
20. Fung W.E. Vitrectomy for chronic aphakic cystoid macular edema; results of a national, collaborative, prospective, randomized investigation; the Vitrectomy-ACME Study Group. Ophthalmology 92 (1985) 1102-1111 discussion by T Hanscom, 1111
21. Harbour J.W., Smiddy W.E., Rubsamen P.E., et al. Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. Am J Ophthalmol 120 (1995) 302-307
22. Miyake K., and Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 47 suppl 1 (2002) S203-S218
23. Noma H., Minamoto A., Funatsu H., et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244 (2006) 309-315
24. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
25. Tolentino M.J., McLeod D.S., Taomoto M., et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133 (2002) 373-385
26. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
27. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (2006) 275-278
28. Michels S., Rosenfeld P.J., Puliafito C.A., et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration; twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112 (2005) 1035-1047
29. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
30. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion; a short-term study. Retina 26 (2006) 279-284
31. Mason III J.O., Albert Jr. M.A., and Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina 26 (2006) 356-357
32. Shahar J., Avery R.L., Heilweil G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (2006) 262-269
33. Manzano R.P.A., Peyman G.A., Khan P., and Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261
34. Wu L., Martínez-Castellanos M.A., Quiroz-Mercado H., et al. Twelve month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol (2007 Aug 3) [Epub ahead of print]
35. Nguyen Q.D., Tatlipinar S., Shah S.M., et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142 (2006) 961-969
36. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005